NAUT · Nautilus Biotechnology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.71M | - | $9.61M | $10.39M | $11.54M | - | $12.29M | $12.44M | $12.93M | - |
| SG&A | $7.31M | - | $5.87M | $6.70M | $7.31M | - | $6.81M | $8.35M | $8.68M | - |
| Total Operating Expenses | $16.12M | - | $15.47M | $17.10M | $18.84M | - | $19.10M | $20.79M | $21.61M | - |
| D&A | $334.0K | - | $400.0K | $400.0K | $465.0K | - | $500.0K | $500.0K | $516.0K | - |
| Operating Income | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($14.70M) | - | ($13.57M) | ($15.03M) | ($16.61M) | - | ($16.45M) | ($18.01M) | ($18.73M) | - |
| EPS - Basic | ($0.12) | - | ($0.11) | ($0.12) | ($0.13) | - | ($0.13) | ($0.14) | ($0.15) | - |
| EPS - Diluted | ($0.12) | - | ($0.11) | ($0.12) | ($0.13) | - | ($0.13) | ($0.14) | ($0.15) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.63M | $12.39M | $23.88M | $34.46M | $33.24M | $27.65M | $4.41M | $24.89M | $25.73M | $19.40M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $300.0K | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.19M | $943.0K | $893.0K | $974.0K | $841.0K | $987.0K | $1.49M | $1.63M | $1.86M | $1.64M |
| Current Assets | $98.83M | $105.96M | $134.32M | $150.72M | $141.60M | $132.83M | $144.21M | $170.93M | $185.09M | $176.84M |
| Total Assets | $177.78M | $191.11M | $200.91M | $213.19M | $227.69M | $242.74M | $259.70M | $272.75M | $288.65M | $305.56M |
| Current Liabilities | $8.34M | $7.95M | $8.98M | $8.14M | $8.16M | $7.63M | $8.66M | $8.68M | $9.21M | $9.12M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $33.36M | $34.14M | $31.78M | $32.09M | $33.26M | $34.01M | $36.27M | $37.47M | $39.16M | $40.21M |
| Stockholders' Equity | $144.41M | $156.97M | $169.14M | $181.09M | $194.44M | $208.73M | $223.43M | $235.28M | $249.49M | $265.35M |
| Retained Earnings | ($346.72M) | ($332.02M) | ($318.24M) | ($304.67M) | ($289.63M) | ($273.02M) | ($255.43M) | ($238.98M) | ($220.97M) | ($202.24M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.10M) | - | - | - | ($13.94M) | - | - | - | ($16.27M) | - |
| Investing Cash Flow | $14.23M | - | - | - | $19.51M | - | - | - | $22.35M | - |
| Financing Cash Flow | $1.10M | - | - | - | $18.0K | - | - | - | $245.0K | - |
| CapEx | $510.0K | - | - | - | $219.0K | - | - | - | $647.0K | - |
| Free Cash Flow | ($13.61M) | - | - | - | ($14.16M) | - | - | - | ($16.91M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.93 | - | - | - | 0.85 | - | - | - | 0.90 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.3% | - | -6.8% | -7.1% | -7.3% | - | -6.3% | -6.6% | -6.5% | - |
| Return on equity | -10.2% | - | -8.0% | -8.3% | -8.5% | - | -7.4% | -7.7% | -7.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.85 | 13.33 | 14.95 | 18.52 | 17.36 | 17.40 | 16.65 | 19.69 | 20.09 | 19.39 |
| Quick ratio | 11.81 | 13.33 | 14.95 | 18.52 | 17.36 | 17.40 | 16.65 | 19.69 | 20.09 | 19.39 |
| Cash ratio | 1.75 | 1.56 | 2.66 | 4.23 | 4.08 | 3.62 | 0.51 | 2.87 | 2.79 | 2.13 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.23 | 1.22 | 1.19 | 1.18 | 1.17 | 1.16 | 1.16 | 1.16 | 1.16 | 1.15 |
| Liabilities / Assets | 0.19 | 0.18 | 0.16 | 0.15 | 0.15 | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.4x | - | 0.6x | 0.5x | 0.6x | - | 1.6x | 1.2x | 1.5x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | 11.5% | - | 17.5% | 16.5% | 11.3% | - | -3.6% | -13.9% | -25.2% | - |
| EPS growth (YoY) | 7.7% | - | 15.4% | 14.3% | 13.3% | - | 0.0% | -7.7% | -25.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 3.9% | - | - | - | 16.3% | - | - | - | -28.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -25.7% | -24.8% | -24.3% | -23.0% | -22.1% | -21.3% | -19.4% | -18.8% | -17.9% | -15.7% |
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Nautilus Biotechnology against the 5 most active filers in the same SIC group.